Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Director Marla L. Kessler Sells 7,610 Shares

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWDGet Rating) Director Marla L. Kessler sold 7,610 shares of the stock in a transaction dated Tuesday, June 14th. The shares were sold at an average price of $11.65, for a total transaction of $88,656.50. Following the completion of the transaction, the director now directly owns 84,148 shares of the company’s stock, valued at $980,324.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

NASDAQ IRWD opened at $11.27 on Friday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 4.82 and a current ratio of 4.82. The company has a 50-day simple moving average of $11.77 and a 200-day simple moving average of $11.60. The firm has a market capitalization of $1.73 billion, a PE ratio of 3.53 and a beta of 1.17. Ironwood Pharmaceuticals, Inc. has a one year low of $10.13 and a one year high of $14.27.

Ironwood Pharmaceuticals (NASDAQ:IRWDGet Rating) last posted its earnings results on Thursday, May 5th. The biotechnology company reported $0.21 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.27 by ($0.06). The firm had revenue of $97.53 million for the quarter, compared to analyst estimates of $96.62 million. Ironwood Pharmaceuticals had a net margin of 124.83% and a return on equity of 34.67%. The company’s revenue for the quarter was up 9.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.24 earnings per share. Equities analysts forecast that Ironwood Pharmaceuticals, Inc. will post 1.17 earnings per share for the current year.

A number of institutional investors have recently bought and sold shares of the business. Norges Bank bought a new stake in shares of Ironwood Pharmaceuticals during the 4th quarter worth about $35,170,000. BlackRock Inc. raised its position in shares of Ironwood Pharmaceuticals by 15.2% during the 4th quarter. BlackRock Inc. now owns 14,368,890 shares of the biotechnology company’s stock worth $167,541,000 after buying an additional 1,897,115 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new stake in shares of Ironwood Pharmaceuticals during the 4th quarter worth about $10,984,000. Royce & Associates LP raised its position in shares of Ironwood Pharmaceuticals by 141.4% during the 1st quarter. Royce & Associates LP now owns 1,160,846 shares of the biotechnology company’s stock worth $14,603,000 after buying an additional 679,997 shares in the last quarter. Finally, Two Sigma Advisers LP raised its position in shares of Ironwood Pharmaceuticals by 403.0% during the 3rd quarter. Two Sigma Advisers LP now owns 602,857 shares of the biotechnology company’s stock worth $7,873,000 after buying an additional 483,000 shares in the last quarter.

A number of analysts recently issued reports on IRWD shares. StockNews.com upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday. Piper Sandler initiated coverage on shares of Ironwood Pharmaceuticals in a research note on Friday, April 22nd. They issued an “overweight” rating and a $16.00 target price on the stock. One research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $15.00.

Ironwood Pharmaceuticals Company Profile (Get Rating)

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union.

Featured Articles

Insider Buying and Selling by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Want More Great Investing Ideas?

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.